#Sweden #Stockholm #Moberg Pharma #MOB-015 #Terbinafine

Recent Breakthroughs in Antifungal Research

On October 5, 2026, Moberg Pharma AB announced significant findings from a new study published in the Journal of Fungi, showcasing the impressive antifungal properties of terbinafine. This study specifically focuses on its effectiveness against dermatophytes responsible for onychomycosis, a common nail fungal infection.

Study Overview

The analyses conducted were based on substantial data gathered from a Phase 3 clinical trial, which involved 506 dermatophyte isolates taken from patients suffering from onychomycosis. Among these isolates, only a minimal 3.2% displayed elevated Minimum Inhibitory Concentration (MIC) values, indicating that the majority remained susceptible to terbinafine.

Critically, one of the most encouraging findings was the mycological cure rate achieved with Moberg Pharma's topical treatment, MOB-015, which reached an impressive 74.3% among patients who provided evaluable results at the end of the treatment period. Notably, this included two out of three patients whose baseline fungi isolates showed higher MIC values.

Collaborative Research Efforts

The research was carried out in collaboration with Professor Mahmoud Ghannoum from Case Western Reserve University in Cleveland, Ohio. The findings are vital in a context of rising antifungal resistance, offering hope that terbinafine can effectively combat these strains.

Amir Tavakkol, Chief Scientific Officer at Moberg Pharma, commented, "These results are particularly reassuring given the increasing concern over antifungal resistance. Terbinafine demonstrated strong activity against most isolates, and MOB-015 successfully achieved mycological cure across the spectrum of initial susceptibility. Our findings reinforce the scientific basis for using MOB-015."

Implications for the Market and Patients

Moberg Pharma's drug, MOB-015, which has received market approval in 14 countries, is poised to be a leading treatment for onychomycosis. This new data adds momentum to its role in combating nail fungus effectively, especially given the increasing number of patients with resistant strains of dermatophytes. With clinical trials that have included over 800 patients, the potential for MOB-015 to dominate the market seems promising, and it is already available in Sweden, Norway, and Israel under the brand name Terclara®.

The research has broader implications as well. The continuous monitoring of antifungal susceptibility and the ability to provide topical treatments will be crucial as the medical community grapples with the growing issue of resistant fungal infections.

Next Steps for Patients

For patients and healthcare providers, the study’s results underline the importance of understanding the susceptibility patterns of fungal infections and tailoring treatments accordingly. As we witness growing rates of mycological cures with MOB-015, patients suffering from onychomycosis can have renewed hope in their treatment journey.

For further details regarding the publication, interested parties can reference the article titled 'In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial,' featured in the Journal of Fungi. This document provides comprehensive insights into the findings and future possibilities associated with MOB-015’s clinical efficacy.

In conclusion, Moberg Pharma's latest research marks a significant advancement in the fight against nail fungus, showcasing the efficacy of terbinafine and solidifying MOB-015's position as a key player in antifungal therapy.